CNC241213P75000
- 0.00
- 0.000.00%
Centene Newsroom
Neurocrine Wins FDA Nod for CAH Therapy
Sector Update: Health Care Stocks Edge Higher Late Afternoon
Centene Stock Undervalued After Clarity Emerges on Post-ACA Subsidy Expiration, UBS Says
Unusual Options Activity: PINS, BRKR and Others Attract Market Bets, PINS V/OI Ratio Reaches 892.9
EST Dec 13th Morning Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
Centene Shares Are Trading Higher After the UBS Upgraded the Stock From Neutral to Buy and Raised Its Price Target From $79 to $80. Also, Barclays Maintained an Overweight Rating on the Stock and Raised Its Price Target From $91 to $93.
Centene Is Maintained at Buy by Truist Securities
Barclays Maintains Overweight on Centene, Raises Price Target to $93
Centene Unveils Its 2025 Guidance, Reaffirms 2024 Outlook
This PayPal Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Express News | Centene Corp : UBS Raises Target Price to $80 From $79
Centene Is Maintained at Outperform by Oppenheimer
Wells Fargo Maintains Centene(CNC.US) With Buy Rating, Raises Target Price to $76
Oppenheimer Maintains Centene(CNC.US) With Buy Rating, Cuts Target Price to $85
A Quick Look at Today's Ratings for Centene(CNC.US), With a Forecast Between $73 to $93
Oppenheimer Reaffirms Their Buy Rating on Centene (CNC)
Analysts Are Bullish on These Healthcare Stocks: Medios AG (MEDOF), Centene (CNC)
Centene Raised to Buy From Neutral by UBS
Truist Securities Adjusts Price Target on Centene to $84 From $89
Stephens Cuts Price Target on Centene to $73 From $75, Keeps Equalweight Rating
Centene Analyst Ratings